ERBB2 and breast cancer: Moreover, in the subgroup of patients ≥ 70 years with cN0, HR + , and HER2- BC, the updated Canadian ASCO guidelines recommend omission of SLNB if adjuvant endocrine treatment is prescribed [3, 4].